标题
Lecanemab
作者
关键词
-
出版物
NEUROLOGY
Volume 101, Issue 15, Pages 661-665
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-07-22
DOI
10.1212/wnl.0000000000207505
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lecanemab Gains FDA Approval for Early Alzheimer Disease
- (2023) Howard D. Larkin JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke
- (2023) Nicholas J. Reish et al. NEW ENGLAND JOURNAL OF MEDICINE
- National trends in prescription drug expenditures and projections for 2022
- (2022) Eric M Tichy et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
- (2022) Charles G. Withington et al. Frontiers in Neurology
- The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
- (2022) Amir Abbas Tahami Monfared et al. Neurology and Therapy
- Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis
- (2022) Kun-Han Lee et al. AGE AND AGEING
- Lecanemab for Alzheimer's disease: tempering hype and hope
- (2022) The Lancet LANCET
- Costs and Utilization of New-to-Market Neurologic Medications
- (2022) Evan L Reynolds et al. NEUROLOGY
- Lecanemab in Early Alzheimer’s Disease
- (2022) Christopher H. van Dyck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
- (2021) Konstantinos I. Avgerinos et al. AGEING RESEARCH REVIEWS
- Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
- (2018) Ron Brookmeyer et al. Alzheimers & Dementia
- Gabapentinoid Use in the United States 2002 Through 2015
- (2018) Michael E. Johansen JAMA Internal Medicine
- Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system
- (2017) Jenna Wong et al. BMJ-British Medical Journal
- Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system
- (2017) Jenna Wong et al. BMJ-British Medical Journal
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
- (2016) Ziad Hijazi et al. LANCET
- Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
- (2016) Allison Keshishian et al. THROMBOSIS AND HAEMOSTASIS
- Predicting Functional Outcome and Symptomatic Intracranial Hemorrhage in Patients With Acute Ischemic Stroke
- (2015) George Ntaios et al. STROKE
- Modeling Test and Treatment Strategies for Presymptomatic Alzheimer Disease
- (2014) James F. Burke et al. PLoS One
- Cholinesterase Inhibitor and N-Methyl-D-Aspartic Acid Receptor Antagonist Use in Older Adults with End-Stage Dementia: A Survey of Hospice Medical Directors
- (2009) Joseph W. Shega et al. JOURNAL OF PALLIATIVE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started